MCM
KRYS icon

Moore Capital Management’s Krystal Biotech KRYS Stock Holding History

Moore Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,500
Closed -$260K – 320
2018
Q4 		$260K Buy
+12,500
New +$262K 0.01% 208

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Moore Capital Management's KRYS Position: Q1 2019 in Review

Moore Capital Management sold out of Krystal Biotech (KRYS) in Q1 2019, closing a stake of 12,500 shares — an estimated $260K sold.

Moore Capital Management first reported a position in KRYS in Q4 2018 and held it in 1 quarter. The position peaked at $260K in Q4 2018. 57 funds tracked by Wall St. Rank hold KRYS as of Q1 2019.

  • Moore Capital Management reported no remaining Krystal Biotech position as of Q1 2019 after selling out during the quarter.
  • Moore Capital Management sold 12,500 Krystal Biotech shares in Q1 2019, an estimated $260K.
  • Moore Capital Management first reported a position in Krystal Biotech in Q4 2018 and held it in 1 quarter.
  • Moore Capital Management's Krystal Biotech position peaked at $260K in Q4 2018.
  • 57 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2019.

Based on Moore Capital Management's 13F filing for Q1 2019, filed 15 May 2019.